Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P51532 (transcriptional activator)
 6,546 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

OBJECTIVE Glioblastoma (GBM) is the most common and lethal type of malignant glioma. The Cancer Genome Atlas divides the gene expression-based classification of GBM into classical, mesenchymal, neural, and proneural subtypes, which is important for understanding GBM etiology and for designing effective personalized therapy. Signal transducer and activator of transcription 3 (STAT3), a critical transcriptional activator in tumorigenesis, is persistently phosphorylated and associated with an unfavorable prognosis in GBM. Although a set of specific targets has been identified, there have been no systematic analyses of STAT3 signaling based on GBM subtype. METHODS This study compared STAT3-associated messenger RNA, protein, and microRNA expression profiles across different subtypes of GBM. RESULTS The analyses revealed a prominent role for STAT3 in the mesenchymal but not in other GBM subtypes, which can be reliably used to classify patients with mesenchymal GBM into 2 groups according to phosphorylated STAT3 expression level. Differentially expressed genes suggest an association between Notch and STAT3 signaling in the mesenchymal subtype. Their association was validated in the U87 cell, a malignant glioma cell line annotated as mesenchymal subtype. Specific associated proteins and microRNAs further profile the STAT3 signaling among GBM subtypes. CONCLUSIONS These findings suggest a prominent role for STAT3 signaling in mesenchymal GBM and highlight the importance of identifying signaling pathways that contribute to specific cancer subtypes.
 ...
PMID:Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma. 2696 88

Background: Glioma is considered one of the most prevalent and lethal brain tumors. Glioblastoma (GBM) is a main subtype of glioma. Long non-coding RNAs (lncRNAs) are identified as a new class of biomarkers and therapeutic targets for treatment of GBM. Objective: In the present study, we focused on exploring the function and potential mechanistic regulation of lncRNA small nucleolar RNA host gene 5 (SNHG5) in GBM. Methods: Gene expression was determined by qRT-PCR or western blot, as appropriate. CCK-8 and EdU assays, flow cytometry analysis and caspase 3 activity assay were conducted to evaluate several cellular processes in GBM cells. The relationship between YY1 and SNHG5 was assessed via ChIP and luciferase reporter assays. Results: SNHG5 was highly expressed in GBM. Loss- and gain-of-function assays revealed that SNHG5 promoted GBM cell proliferation and inhibited cell apoptosis in GBM. Mechanism experiments proved Yin Yang 1 (YY1) as transcriptional activator of SNHG5 in GBM. More importantly, we found that SNHG5 played the oncogenic role in GBM by activating p38/MAPK signaling pathway. Conclusion: YY1-induced SNHG5 promoted the cell proliferation in GBM via p38/MAPK signaling pathway. The findings expanded our understanding of SNHG5 as an oncogene in GBM.
 ...
PMID:YY1-Activated Long Noncoding RNA SNHG5 Promotes Glioblastoma Cell Proliferation Through p38/MAPK Signaling Pathway. 3165 21